Literature DB >> 2873219

The binding of amsacrine to human plasma proteins.

J W Paxton, J L Jurlina, S E Foote.   

Abstract

Determination of amsacrine plasma protein binding by both equilibrium dialysis and ultracentrifugation gave similar results and indicated that amsacrine is highly bound (approximately 97%) in human plasma. This binding is independent of amsacrine concentration over the range 1-100 mumol litre-1, but is very sensitive to plasma pH and, to a lesser extent, to temperature. Approximately 20% of the drug appeared to be covalently bound to plasma proteins. Amsacrine was bound by all plasma proteins investigated including albumin, alpha 1-acid glycoprotein and various gamma-globulins. The binding to albumin appeared to occur by two processes, a saturable process at a single site with a KD of 13.9 mumol litre-1 and a non-saturable process. Despite differences in individual protein concentrations, no significant difference was observed in the unbound amsacrine fraction in plasma from patients receiving this drug for treatment of acute myelogenous leukaemia and plasma from healthy individuals.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873219     DOI: 10.1111/j.2042-7158.1986.tb04606.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

Review 1.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III. Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit.

Authors:  J W Paxton; S E Foote; R M Singh
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.

Authors:  S Zhou; R Chin; P Kestell; M D Tingle; J W Paxton
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

4.  Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.

Authors:  Dierk Thomas; Bettina C Hammerling; Kezhong Wu; Anna-Britt Wimmer; Eckhard K Ficker; Glenn E Kirsch; Mary C Kochan; Barbara A Wible; Eberhard P Scholz; Edgar Zitron; Sven Kathöfer; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

5.  The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.

Authors:  J W Paxton; J R Hardy; P C Evans; V J Harvey; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia.

Authors:  W P Petros; J H Rodman; J Mirro; W E Evans
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.